What laboratory tests should be ordered to evaluate secondary causes of hypertension in a 30-year-old patient with newly diagnosed hypertension?

Laboratory Evaluation for Secondary Hypertension in Young Patients

In a 30-year-old patient with newly diagnosed hypertension, start with basic screening labs (comprehensive metabolic panel, CBC, lipid profile, TSH, urinalysis, and ECG), then proceed to targeted testing based on clinical suspicion—specifically obtaining an aldosterone-to-renin ratio before starting antihypertensive medications, as primary aldosteronism is the most common endocrine cause in this age group. 1, 2

Initial Basic Laboratory Panel

All young patients with newly diagnosed hypertension require baseline screening to identify secondary causes and assess cardiovascular risk 1:

Essential basic tests include:

• Comprehensive metabolic panel (sodium, potassium, calcium, creatinine with eGFR, fasting glucose) 1
• Complete blood count 1
• Lipid profile 1
• Thyroid-stimulating hormone (TSH) 1
• Urinalysis 1
• Electrocardiogram 1

Key Clinical Context for Young Patients

Young patients (≤30 years) warrant heightened suspicion for secondary causes 1, 3, 4. The pattern of presentation matters significantly: sudden onset hypertension, absence of family history, severe BP elevation (stage 2), or poor response to initial therapy all increase the likelihood of an identifiable secondary cause 1, 3.

Age-Specific Targeted Testing

Primary Aldosteronism Screening (Most Important in This Age Group)

The aldosterone-to-renin ratio (ARR) is the single most important targeted test for young adults with hypertension 5, 2, 6. Primary aldosteronism affects 8-20% of hypertensive patients and is the most common endocrine cause in middle-aged adults 5.

Critical timing consideration: Obtain the ARR before starting antihypertensive medications whenever possible, as many drugs interfere with interpretation 7, 6:

• Beta-blockers, ACE inhibitors, ARBs, and diuretics all affect the ratio 7
• If the patient is already on interfering medications that cannot be stopped, interpretation must account for these effects 6
• Correct hypokalemia before testing, as it lowers aldosterone levels (false negative) 7

Obtain ARR screening if any of the following are present 2:

• Hypokalemia (spontaneous or diuretic-induced)
• Resistant hypertension
• Incidentally discovered adrenal mass
• Family history of early-onset hypertension or stroke at young age (<40 years)
• Obstructive sleep apnea

Renovascular Disease Screening

For adults ≤30 years with elevated brachial BP, measure thigh BP—if lower than arm pressures, suspect coarctation of the aorta 1. This is a critical physical examination finding that should not be missed.

In young women, fibromuscular dysplasia (FMD) is a leading cause of renovascular hypertension 8, 9. Screen with renal Doppler ultrasound, CT angiography, or MR angiography if clinical clues suggest renovascular disease 7, 8:

• Abdominal bruit (particularly in young women without atherosclerosis risk factors)
• Unexplained kidney size asymmetry (>1.5 cm difference)
• Family history of FMD
• FMD in another vascular territory

Renal Parenchymal Disease

The basic metabolic panel already captures key markers 1, 3:

• Serum creatinine with eGFR
• Urinalysis for blood and protein
• Add urinary albumin-to-creatinine ratio if initial urinalysis is abnormal or if diabetes/CKD is suspected 1, 7
• Renal ultrasound if abnormalities detected 7, 3

Additional Screening Based on Clinical Clues

Only pursue these if specific symptoms or signs are present 1, 10:

Pheochromocytoma (if episodic symptoms: headaches, palpitations, sweating, pallor):

• 24-hour urinary or plasma metanephrines and normetanephrines 7, 3

Cushing's syndrome (if central obesity, facial rounding, easy bruising, striae):

• 24-hour urinary free cortisol or low-dose dexamethasone suppression test 7, 3

Obstructive sleep apnea (if snoring, daytime sleepiness, obesity, neck circumference >40 cm):

• Overnight polysomnography 5, 7, 3
• Recent evidence shows OSA may be present in up to 84.5% of hypertensive patients and is the most common identifiable contributor 11

Common Pitfalls to Avoid

1. Don't delay ARR testing until after starting medications—many antihypertensives interfere with accurate interpretation 7, 6

2. Don't assume normal potassium excludes primary aldosteronism—only 9-37% of PA patients have hypokalemia 2. The 2025 AHA/ACC guidelines now recommend screening for PA in resistant hypertension regardless of whether hypokalemia is present 2

3. Don't forget the thigh BP measurement in young patients—coarctation can be missed if only arm pressures are obtained 1

4. Don't order extensive testing without clinical suspicion—use history and physical examination findings to guide targeted testing 1, 10, 3

5. Don't overlook medication and substance history—NSAIDs, oral contraceptives, cocaine, amphetamines, and alcohol can all cause or worsen hypertension 1

When to Refer to Specialist

Consider referral to a hypertension specialist if 5, 3, 2:

• Positive screening test for secondary cause requiring confirmatory testing
• Resistant hypertension (BP above target despite 3 drugs including a diuretic)
• Severe hypertension (stage 2) in a young patient
• Rapid onset or sudden worsening of previously controlled hypertension
• Target organ damage disproportionate to BP severity or duration

The 2024 ESC guidelines emphasize that resistant hypertension should be managed in specialist centers with sufficient expertise 7, and the 2025 AHA/ACC guidelines recommend referral to clinicians with expertise in specific forms of secondary hypertension for diagnostic confirmation and treatment 2, 12.